You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR PITAVASTATIN CALCIUM

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for pitavastatin calcium

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02056847 ↗	to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia	Completed	Ajou University School of Medicine	Phase 4	2013-09-01	Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
NCT02056847 ↗	to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia	Completed	Asan Medical Center	Phase 4	2013-09-01	Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
NCT02056847 ↗	to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia	Completed	Chonbuk National University Hospital	Phase 4	2013-09-01	Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
NCT02056847 ↗	to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia	Completed	Chonnam National University Hospital	Phase 4	2013-09-01	Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
NCT02056847 ↗	to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia	Completed	Chungnam National University Hospital	Phase 4	2013-09-01	Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
NCT02056847 ↗	to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia	Completed	Dong-A University Hospital	Phase 4	2013-09-01	Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
NCT02056847 ↗	to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia	Completed	Eulji University Hospital	Phase 4	2013-09-01	Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for pitavastatin calcium

Condition Name

Chart
Table

Condition Name for pitavastatin calcium
Intervention	Trials
Dyslipidemias	1
HbA1c Level Associated With Lipid Compositions	1
Hypertension	1
Prediabetic State	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for pitavastatin calcium
Intervention	Trials
Hypertension	1
Dyslipidemias	1
Hyperlipoproteinemias	1
Hyperlipidemias	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for pitavastatin calcium

Trials by Country

Map
Table

Trials by Country for pitavastatin calcium
Location	Trials
China	7
Korea, Republic of	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for pitavastatin calcium

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for pitavastatin calcium
Clinical Trial Phase	Trials
Phase 4	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for pitavastatin calcium
Clinical Trial Phase	Trials
Completed	1
Unknown status	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for pitavastatin calcium

Sponsor Name

Chart
Table

Sponsor Name for pitavastatin calcium
Sponsor	Trials
Eulji University Hospital	1
The Catholic Univ. of Korea Daejeon St. Marys Hostpial	1
Gangnam Severance Hospital	1
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for pitavastatin calcium
Sponsor	Trials
Other	26
Industry	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.